Sartorius Ag · XETR:SRT
Sartorius — Sartorius Stedim Biotech — Investor Day (March 2026)
34 slides from Sartorius's investor day presentation, Mar 17, 2026
Slide 1: Sartorius Stedim Biotech Capital Markets Day 2026
Sartorius Stedim Biotech Capital Markets Day 2026 March 17, 2026
Slide 2: Note
Note This presentation contains statements concerning the future performance of Sartorius Stedim Biotech. These statements are based on assumptions and estimates. Although we are convinced that these forward- looking statements are realistic, we cannot guarantee that they will actually materialize.
Slide 3: What we are building on
What we are building on RTORILS
Slide 4: Anchored in purpose – Ambitious to shape the future
Anchored in purpose – Ambitious to shape the future Our Better health for more people. Purpose We empower biopharma customers to accelerate drug Our development and enhance manufacturing efficiency Mission for better therapies and more affordable medicine. Our Simplifying Progress Promise 4 Capital
Slide 5: A leading biologics pure play with unique strengths in single-use
A leading biologics pure play with unique strengths in single-use Strong focus Highly differentiated end-to-end portfolio; leading market positions on biopharma Unique Deep scientific, application and regulatory expertise know-how Trusted Superior and consistent quality and global technical support
Slide 6: Compelling business profile in a ten years perspective
Compelling business profile in a ten years perspective Track record of profitable growth above market High revenue share with Life Sciences customers Sales Ø Annual margin ~13% CAGR ~50bps expansion 2025 ~90% Revenue share today ~€3.0bn 30.8 % 2015 ~€0.9bn 26.2% 2015 2025 Sales revenue ul. EBITDA ma
Slide 7: Continuous portfolio expansion through innovation
Continuous portfolio expansion through innovation Strengthened portfolio in three key areas mainly through M&A Strong innovation engine ▪ Closed gaps in downstream offering Own product development Chromatography ▪ True end-to-end portfolio in areas of core competencies ▪ Built an early position in e
Slide 8: Addressing the complex and regulated biopharma value chain
Addressing the complex and regulated biopharma value chain 1 Cell line & process development Creation of a stable cell line; definition of a robust manufacturing process 2 Upstream & downstream production Production, isolation and filling of the desired drug Sartorius offers an integrated, fully sca
Slide 9: A scalable single-use platform for efficient biopharma manufacturing
A scalable single-use platform for efficient biopharma manufacturing Our ambition Scalable end-to-end solutions for all biopharmaceutical modalities; More efficient bioprocessing Market leader in single-use technologies Design safe and flexible Media & reagents Bioreactors processes Reduce investmen
Slide 10: Attractive business model with high share of recurring revenue
Attractive business model with high share of recurring revenue Steady recurring revenues supported by validated manufacturing processes and equipment installations ~85% Consumables & reagents Software Service Recurring revenue FY 2025 figures 10 Capital Markets Day 2026
Slide 11: Regulatory validation as a foundation for the resilient Sartorius business model
Regulatory validation as a foundation for the resilient Sartorius business model Customer Cell line & process Clinical trials Commercial workflow development production % of ~10% ~30% ~60% revenue Sales Seed business Win the spec Scale up process Business stickiness Note: Sales split by development
Slide 12: Strong market fundamentals
Strong market fundamentals RTORILS
Slide 13: Sustained strong market fundamentals
Sustained strong market fundamentals Growing and aging Growing pharma Shift in medicine Increasing number of population1 market2 to biologics2 drug approvals2,3 >1.6bn ~5% p.a. ~57% 2x Estimated number of growth of global share of biologics in number of approvals4 in people aged 65+ by 2050 pharma m
Slide 14: Broad growth of biologics; rising relevance of new modalities
Broad growth of biologics; rising relevance of new modalities mAbs remain dominant; biosimilars, AT and next gen antibodies Large number of molecules in pipeline: with strong growth from small base New modalities account for ~50% today Revenue by modality (€ bn)1 Number of molecules in development1
Slide 15: R&D and production volumes as structural market growth drivers
R&D and production volumes as structural market growth drivers Addressable market CAGR mid-term1 Opportunities ▪ Biopharma R&D and production volumes continue to grow, driven by expanding pipelines, drug approvals, and rising patient demand ▪ Increasing complexity and diversity of modalities drive i
Slide 16: Single-use and process intensification: Reshaping bioprocessing
Single-use (SU) and process intensification: Reshaping bioprocessing Biologics manufacturing is evolving Modality mix supports adoption: SU is preferred platform for majority of pipeline modalities ▪ More single-use, even at commercial scale ▪ More intensified, automated, and data-driven ~55% ▪ More
Slide 17: How we shape the future
How we shape the future RTORILS
Slide 18: Strengthening Sartorius Stedim Biotech's competitive edge
Strengthening Sartorius Stedim Biotech`s competitive edge Simplifying progress Financial ambition Profitable growth above market, enhanced cash generation, reduced leverage Strategic Portfolio Customer experience Excellence & efficiency initiatives How to add value to customers How to engage with cu
Slide 19: Sharpening portfolio for above-market growth
Sharpening portfolio for above-market growth Grow the core Our Goal ▪ Focus on high-value, mission Grow ambitiously and expand market critical applications and/or high leadership in our core businesses growth areas ▪ Capture greater share of wallet We stay focused on ▪ Focus on organic business biop
Slide 20: Growing the core across mission-critical bioprocessing and cell analytics
Growing the core across mission-critical bioprocessing and cell analytics ▪ Build on our pioneering position to Pionic Ambr lead single use manufacturing Process Intensification ▪ Maintain leadership through continuous innovation of established product lines Sartopore Celsius Core Single Use ▪ Stren
Slide 21: Advancing future businesses beyond the core: Additional growth vectors
Advancing future businesses beyond the core: Additional growth vectors Specialized solutions built on differentiated raw materials, analytics, and instrument expertise ATS1 Integrated PAT and in-/at-line analytic platforms in manufacturing and quality labs PAT & AC/QC3 1 Advanced Therapy Solutions 2
Slide 22: Enhancing customer experience across the end-to-end journey
Enhancing customer experience across the end-to-end journey Customer expectations across the life science industry Initiatives to enhance customer experience Short lead times, convenient product customization Improving lead times, delivery performance and configurability of our product to enhance cu
Slide 23: Evolving into a more cost-efficient, digitalized and lean organization
Evolving into a more cost-efficient, digitalized and lean organization Operations transformation to achieve best-in-class supply chain performance, product and service quality Factory of the Network Simplify Strengthen future optimization operations sourcing more automation, resilient and clearer fl
Slide 24: Delivering an attractive financial profile
Delivering an attractive financial profile
Slide 25: 2026 as a transition year towards mid-term growth ambition
2026 as a transition year towards mid-term growth ambition Sales revenue growth1, ul. EBITDA margin 12 32.2 What we currently see 32 10 +6-10% 31.8 +9.6% 31.6 8 ▪ Market is showing signs of gradual improvement 31.4 ▪ Equipment business stabilizing, becoming less dilutive 6 31.2 31 to growth 4 Sligth
Slide 26: Sustained outperformance supported by market trends
Sustained outperformance supported by market trends SSB mid-term ambition2 Addressable market SSB key drivers Above-market Organic sales revenue ul EBITDA margin CAGR mid-term1 of outperformance growth p.a. growth p.a. in cc expansion p.a. ▪ Leadership in SU and Sartorius process intensification Ste
Slide 27: Long-term margin upside embedded in the business model
Long-term margin upside embedded in the business model Expected contribution to Mid-term key assumptions Share of cost positions margin development ▪ Increasing capacity utilization; growing 2019 2025 2026e Mid-term consumables contribution Sales 100% 100% ▪ Cost improvements driven by increasing Co
Slide 28: Higher efficiency through continuous improvement mindset and scalable growth platforms
Higher efficiency through continuous improvement mindset and scalable growth platforms Efficiency program Cost savings of ~€85m with positive margin effects in 2025 2024 as a base Continuous based on Lean/CI thinking to improve cost structures from year to year efficiency initiatives Powerful across
Slide 29: Substantial investments support resilient footprint and future growth
Substantial investments support resilient footprint and future growth Key Focus Areas Freiburg Cell culture reagents Göttingen Songdo Global resilience Membranes, filters, R&D Filters, cell culture media, bags, laboratories, training Marlborough center Redundant capacities Innovation Center for Biop
Slide 30: Strong cash generation and financial flexibility
Strong cash generation and financial flexibility Capex Free Cash Flow in % of revenue 2025 Mid-term Major capex projects 2026 ~13.3% Ul EBITDA margin 30.8% 60-85bps p.a.1 Songdo, South Korea Freiburg, Germany hsd NWC in % of sales 14.8% Slightly down Regular capex composition Capex ratio, % 13.3% hs
Slide 31: Strong focus on deleveraging
Strong focus on deleveraging Continued deleveraging after intense M&A phase Polyplus DHR Disciplined capital deployment LS assets Novasep WaterSep Chroma. ▪ Organic deleveraging the top priority BIA Albumedix ▪ Capex discipline and focused on essential growth and productivity projects CellGenix Biol
Slide 32: Sustainable value creation remains well on track
Sustainable value creation remains well on track Proven strengths that continue to matter ▪ Addressing attractive biopharma end markets with high entry barriers and strong structural growth drivers ▪ Biologics pure-play with a focus on single-use, uniquely positioned to capture above-market growth ▪
Slide 33: Contacts and Financial calendar
Contacts and Financial calendar March 26, 2026 Annual General Meeting April 23, 2026 Publication Q1 Results 2026 Petra Müller May 19, 2026 Head of Investor Relations RBC Global Healthcare Conference, New York +49.551.308.6035 May 26, 2026 petra.mueller2@sartorius.com dbAccess European Champions Conf
Slide 34: Simplifying Progress
Simplifying Progress